Experts have developed a new tool for surgical prioritization and ranking for patients with head and neck cancer in a scarce-resource settings associated with the COVID-19 pandemic.
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
Patients treated with chemotherapy plus radiotherapy had a 64% reduced likelihood of disease progression or death compared with those who underwent chemotherapy alone.
The purpose of this study was to develop and test a gene-expression profiling assay to facilitate patient selection for induction chemotherapy in the setting of LA-NPC.
Increasing trends in global thyroid cancer burden were observed in a cross-sectional study using data from 195 countries in 21 regions.
[Cancer Management and Research] Researchers sought to quantify the effect of the measures taken to reduce transmission of the coronavirus on diagnosis and treatment of nasopharyngeal cancer.
EAT-10 and pain correlated to FOIS scores in patients with HNC for the evaluation of swallowing functionality and ingestion status, whereas other tests were found unnecessary.
The accelerated approval was based on data from a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic solid tumors with TMB-H who were enrolled in the open-label phase 2 KEYNOTE-158 trial.